Literature DB >> 22373564

Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism.

Michael R Rutledge1, Victor Farah, Adedayo A Adeboye, Michael R Seawell, Syamal K Bhattacharya, Karl T Weber.   

Abstract

Aldosteronism, or chronic elevation in plasma aldosterone (ALDO) (inappropriate for dietary Na(+) intake), is accompanied by an adverse structural remodeling of the heart and vasculature. Herein, we bring forward a new perspective in which parathyroid hormone (PTH) is identified as a crucial mediator of pathologic cardiac remodeling in aldosteronism. Secondary hyperparathyroidism (SHPT) appears because of the marked urinary and fecal losses of Ca(2+) and Mg(2+) that accompany aldosteronism which creates ionized hypocalcemia and hypomagnesemia, providing major stimuli to the parathyroids' enhanced secretion of PTH. Invoked to restore extracellular Ca(2+) and Mg(2+) homeostasis, elevations in plasma PTH lead to paradoxical intracellular Ca(2+) overloading of diverse tissues. In the case of cardiomyocytes, the excessive intracellular Ca(2+) accumulation involves both cytosolic free and mitochondrial domains with a consequent induction of oxidative stress by these organelles and lost ATP synthesis. The ensuing opening of their inner membrane permeability transition pore (mPTP) accounts for the osmotic swelling and structural degeneration of mitochondria followed by programed cell necrosis. Tissue repair, invoked to preserve the structural integrity of myocardium accounts for a replacement fibrosis, or scarring, which is found scattered throughout the right and left heart; it represents a morphologic footprint of earlier necrosis. Multiple lines of evidence are reviewed that substantiate the PTH-mediated paradigm and the mitochondriocentric signal-transducer-effector pathway to cardiomyocyte necrosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22373564     DOI: 10.1007/s10557-012-6378-0

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  17 in total

1.  Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure.

Authors:  G Loncar; B Bozic; N Cvetinovic; H-D Dungen; M Lainscak; S von Haehling; W Doehner; Z Radojicic; B Putnikovic; T Trippel; V Popovic
Journal:  J Endocrinol Invest       Date:  2016-10-13       Impact factor: 4.256

2.  Cinacalcet ameliorates cardiac fibrosis in uremic hearts through suppression of endothelial-to-mesenchymal transition.

Authors:  Min Wu; Ri-Ning Tang; Hong Liu; Ming-Ming Pan; Lin-Li Lv; Jian-Dong Zhang; Steven D Crowley; Bi-Cheng Liu
Journal:  Int J Cardiol       Date:  2013-12-07       Impact factor: 4.164

Review 3.  Vitamin D and cardiovascular disease prevention.

Authors:  Stefan Pilz; Nicolas Verheyen; Martin R Grübler; Andreas Tomaschitz; Winfried März
Journal:  Nat Rev Cardiol       Date:  2016-05-06       Impact factor: 32.419

Review 4.  Zinc and the prooxidant heart failure phenotype.

Authors:  Nephertiti Efeovbokhan; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2014-10       Impact factor: 3.105

Review 5.  Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence.

Authors:  Martin Robert Grübler; Winfried März; Stefan Pilz; Tanja B Grammer; Christian Trummer; Christian Müllner; Verena Schwetz; Marlene Pandis; Nicolas Verheyen; Andreas Tomaschitz; Antonella Fiordelisi; Daniela Laudisio; Ersilia Cipolletta; Guido Iaccarino
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

Review 6.  Phosphate imbalance in patients with heart failure.

Authors:  E C Christopoulou; T D Filippatos; E Megapanou; M S Elisaf; G Liamis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 7.  Muscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role?

Authors:  Nabanita S Datta
Journal:  Endocrine       Date:  2014-05-07       Impact factor: 3.633

8.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

9.  Heart valve disease: the role of calcidiol deficiency, elevated parathyroid hormone levels and oxidative stress in mitral and aortic valve insufficiency.

Authors:  Esin Eren; Hamit Yasar Ellidag; Yesim Cekin; Raif Umut Ayoglu; Ali Osman Sekercioglu; Necat Yılmaz
Journal:  Redox Rep       Date:  2013-11-26       Impact factor: 4.412

10.  Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study.

Authors:  Nicolas D Verheyen; Katharina Kienreich; Martin Gaksch; Adriana J van Ballegooijen; Martin R Grübler; Briain Ó Hartaigh; Johannes Schmid; Astrid Fahrleitner-Pammer; Elisabeth Kraigher-Krainer; Caterina Colantonio; Evgeny Belyavskiy; Gerlies Treiber; Cristiana Catena; Helmut Brussee; Burkert Pieske; Winfried März; Andreas Tomaschitz; Stefan Pilz
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.